Dantrolene
| 證據等級: L5 | 預測適應症: 9 個 |
目錄
Dantrolene: Drug Repurposing Evaluation — Insufficient Data for Assessment
One-Sentence Summary
Dantrolene (DrugBank: DB01219) is currently under data collection review for drug repurposing analysis. This Evidence Pack contains no TxGNN predicted indications, and critical data gaps remain in mechanism of action and safety profiling — a complete data refresh is required before any repurposing evaluation can proceed.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in current Evidence Pack |
| Predicted New Indication | No TxGNN prediction available |
| TxGNN Prediction Score | — |
| Evidence Level | Not applicable — no prediction received |
| New Zealand Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Data Completeness Assessment
This Evidence Pack cannot support a standard drug repurposing evaluation. The table below summarises the critical gaps identified during data collection:
| Data Item | Query Status | Impact |
|---|---|---|
| TxGNN Predicted Indications | Not received (predicted_indications: []) |
Cannot identify or evaluate any repurposing direction |
| Mechanism of Action (MOA) | DrugBank queried successfully, but MOA not extracted | Cannot assess mechanistic plausibility for any candidate indication |
| Key Warnings / Contraindications | TFDA package insert queried successfully, but data not extracted | Cannot complete safety pre-screening |
| Original Approved Indications | No records found in TFDA database | Cannot anchor repurposing logic to known clinical use |
| Drug–Drug Interactions | Not found | Cannot assess interaction risk |
Note: The DrugBank query (Log ID 3) and TFDA package insert query (Log ID 4) both returned
result_status: success, which suggests the underlying data exists but was not surfaced into the Evidence Pack. Re-running the extraction pipeline is likely sufficient to resolve most gaps.
New Zealand Market Information
Dantrolene currently holds no product authorisations in New Zealand. There are no licensed products, dosage forms, or approved indications on record in this dataset.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: No TxGNN predicted indication is present in this Evidence Pack, and the absence of MOA, safety warnings, and approved indication data makes it impossible to perform even a preliminary plausibility or risk assessment. Proceeding without this information would not meet the minimum standard for a drug repurposing evaluation.
To proceed, the following is needed:
- Re-run TxGNN prediction pipeline to obtain scored predicted indications for Dantrolene (DB01219)
- Extract MOA from DrugBank — the query succeeded (Log ID 3), so the data is available; re-run the extraction step
- Extract key warnings and contraindications from TFDA package insert — the query succeeded (Log ID 4); re-run the parsing step
- Confirm original approved indications from DrugBank or international regulatory sources (e.g., FDA, EMA), since TFDA holds no records
- Re-check DDI database with alternate search terms or identifiers (e.g., DrugBank ID rather than INN) if the INN query continues to return no results
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.